Two of the Alliance sites, Hassman Research Institute (HRI) and Collaborative Neuroscience Network (CNS), collaborated to develop a self-funded empirical investigation assessing how a Placebo-Control Reminder Script (PCRS) educating subjects about key factors associated with placebo response in clinical trials might help manage this insidious effect within our industry. They presented their positive results at…
Read MorePosts by Clinical Trial Centers
NeuroCog Trials is now VeraSci Durham, NC—October 12, 2018—NeuroCog Trials announced today that they are changing their name to VeraSci and have rebranded all of their materials and website to better represent their current position as comprehensive collaborative partners in scientific discovery. They are also merging NeuroCog Trials with NCT Linguistics, formerly a…
Read MoreOctober 15-16, Alliance representatives are attending the International Society for CNS Clinical Trials and Methodology (ISCTM) Autumn Conference in Marina del Ray, CA. November 1-4, we’ll be in Boca Raton, FL for CNS Summit. We look forward to hearing from knowledgeable speakers, and meeting with industry associates to discuss our capabilities and extensive…
Read MoreOctober 10-11, Alliance representatives are attending the 12th Annual Pain & Migraine Therapeutics Summit in San Francisco, CA. December 11-13, we’ll be in Boston for the inaugural World Migraine Forum. We look forward to hearing from knowledgeable speakers and meeting with industry associates to discuss our capabilities and extensive experience with pain and…
Read MoreAlliance representatives are attending the following Outsourcing conferences: Outsourcing in Clinical Trials Southern California 2018 September 26–27 in La Jolla, CA Outsourcing in Clinical Trials Pacific Northwest 2018 October 16-17 in Vancouver, BC Outsourcing in Clinical Trials New England 2018 November 6-7 in Boston, MA We look forward to learning about sponsors’ outsourcing challenges, and…
Read MoreJuly 22-26, Alliance representatives are attending the Alzheimer’s Association International Conference® (AAIC) in Chicago. July 30-August 1, we’ll be in Boston for the Neuropsychiatric Drug Development Summit (NDD). We look forward to hearing from knowledgeable speakers and meeting with industry associates to discuss our capabilities and extensive experience with Alzheimer’s and other mental…
Read MoreDr. Kathleen Anne Welsh-Bohmer, a leading scientific expert in Alzheimer’s Disease (AD) research, has joined NeuroCog Trials (NCT) as the Vice President of Neurodegenerative Disorders. Dr. Welsh-Bohmer will lead the ongoing development of new technology and tools such as wearables and custom in-house assessments, designed to support customers conducting clinical trials for dementia and…
Read MoreAlkermes plc today announced that the U.S. Food and Drug Administration (FDA) has approved ARISTADA INITIO™ (aripiprazole lauroxil) for the initiation of ARISTADA® (aripiprazole lauroxil), a long-acting injectable atypical antipsychotic for the treatment of schizophrenia in adults. For the first time, ARISTADA INITIO, in combination with a single 30 mg dose of oral aripiprazole, provides…
Read MoreThe Alliance sites take placebo response within our clinical trials quite seriously – we often lament that it is one constant that keeps our investigators up at night. As such, we engage in a multitude of activities and interventions to manage the placebo effect. For example, one of our research sites, Hassman Research Institute (HRI),…
Read MoreSite Recognition Award commemorates exceptional performance of Collaborative Neuroscience Network.
Read More